• Haemonetics Corporation recently reported publication of a large Emory University retrospective study of 1,623 patients, showing its VASCADE MVP XL venous vascular closure system achieved rapid hemostasis, high same-day discharge rates and a low rate of vascular complications in large-bore sheath electrophysiology procedures following earlier FDA label expansion.
• The findings add real-world backing to VASCADE MVP XL as the only extravascular venous closure system clinically proven in electrophysiology procedures using up to 17F outer diameter sheaths, reinforcing its fit with market-leading pulsed field ablation and left atrial appendage closure technologies.
• Now we’ll examine how this new real-world evidence for VASCADE MVP XL’s rapid hemostasis and same-day discharge profile affects Haemonetics’ investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Haemonetics Investment Narrative Recap

To own Haemonetics, you need to believe its concentrated portfolio in NexSys, TEG and especially VASCADE can keep pulling in profitable, defensible hospital revenue despite U.S. exposure and competition. The new Emory study strengthens the clinical case for VASCADE MVP XL after the 2026 FDA label expansion, but it does not, by itself, resolve the key near term risk that Interventional Technologies growth may still lag expectations if competitors respond aggressively or adoption stalls.

The most relevant recent event here is the March 2026 FDA label expansion for VASCADE MVP XL to include up to 17F outer diameter sheaths. The Emory data now lands on top of that milestone, giving Haemonetics more peer reviewed evidence behind a product that management has highlighted as core to reinvigorating Interventional Technologies. Together, the label expansion and real world outcomes form an important proof point ahead of any further updates on VASCADE growth trends and margin progress.

Yet while the clinical story looks stronger, investors also need to be aware that growing dependence on a few products and the U.S. market could...

Haemonetics' narrative projects $1.5 billion revenue and $247.6 million earnings by 2029. This requires 5.3% yearly revenue growth and about a $72 million earnings increase from $175.4 million today.

Uncover how Haemonetics' forecasts yield a $86.90 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts already assumed revenue of about US$1.6 billion and earnings of roughly US$229.9 million by 2029, yet they still flagged execution risk in VASCADE and reimbursement pressures as reasons the stock might deserve a much lower valuation. This new study could challenge parts of that pessimistic view or reinforce it, depending on how you weigh the added clinical evidence against those longer term concerns.

Explore 2 other fair value estimates on Haemonetics - why the stock might be worth as much as 60% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Haemonetics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Haemonetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Haemonetics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.